Hematologic malignancies following immune checkpoint inhibition for solid tumors

Mick J.M. van Eijs; Lotte E. van der Wagen; Rogier Mous; Roos J. Leguit; Lisette van de Corput; Anne S.R. van Lindert; Britt B.M. Suelmann; Anna M. Kamphuis; Stefan Nierkens; Karijn P.M. Suijkerbuijk

doi:10.1007/s00262-022-03230-4

Hematologic malignancies following immune checkpoint inhibition for solid tumors

Mick J.M. van Eijs
, Lotte E. van der Wagen
, Rogier Mous
, Roos J. Leguit
, Lisette van de Corput
, Anne S.R. van Lindert
, Britt B.M. Suelmann
, Anna M. Kamphuis
, Stefan Nierkens
, Karijn P.M. Suijkerbuijk

Group Nierkens

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.

Original language	English
Pages (from-to)	249-255
Number of pages	7
Journal	Cancer Immunology, Immunotherapy
Volume	72
Issue number	1
DOIs	https://doi.org/10.1007/s00262-022-03230-4
Publication status	Published - 13 Jun 2022

Keywords

Hematologic Neoplasms/drug therapy
Humans
Immune Checkpoint Inhibitors/therapeutic use
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Leukemia, Myeloid, Acute
Myelodysplastic Syndromes/drug therapy

Access to Document

10.1007/s00262-022-03230-4

Cite this

@article{88046840e86145e68b3b881015e93406,

title = "Hematologic malignancies following immune checkpoint inhibition for solid tumors",

abstract = "Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.",

keywords = "Hematologic Neoplasms/drug therapy, Humans, Immune Checkpoint Inhibitors/therapeutic use, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Myelodysplastic Syndromes/drug therapy",

author = "\{van Eijs\}, \{Mick J.M.\} and \{van der Wagen\}, \{Lotte E.\} and Rogier Mous and Leguit, \{Roos J.\} and \{van de Corput\}, Lisette and \{van Lindert\}, \{Anne S.R.\} and Suelmann, \{Britt B.M.\} and Kamphuis, \{Anna M.\} and Stefan Nierkens and Suijkerbuijk, \{Karijn P.M.\}",

note = "{\textcopyright} 2022. The Author(s).",

year = "2022",

month = jun,

day = "13",

doi = "10.1007/s00262-022-03230-4",

language = "English",

volume = "72",

pages = "249--255",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "1",

}

TY - JOUR

T1 - Hematologic malignancies following immune checkpoint inhibition for solid tumors

AU - van Eijs, Mick J.M.

AU - van der Wagen, Lotte E.

AU - Mous, Rogier

AU - Leguit, Roos J.

AU - van de Corput, Lisette

AU - van Lindert, Anne S.R.

AU - Suelmann, Britt B.M.

AU - Kamphuis, Anna M.

AU - Nierkens, Stefan

AU - Suijkerbuijk, Karijn P.M.

PY - 2022/6/13

Y1 - 2022/6/13

N2 - Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.

AB - Immune checkpoint inhibition (ICI) can induce durable responses in patients with advanced malignancies. Three cases of hematological neoplasia following ICI for solid tumors have been reported to date. We present five patients treated at our tertiary referral center between 2017 and 2021 who developed chronic myeloid leukemia (two patients), acute myeloid leukemia, myelodysplastic syndrome and chronic eosinophilic leukemia during or after anti-PD-1-based treatment. Molecular analyses were performed on pre-ICI samples to identify baseline variants in myeloid genes. We hypothesize that PD-1 blockade might accelerate progression to overt myeloid malignancies and discuss potential underlying mechanisms.

KW - Hematologic Neoplasms/drug therapy

KW - Humans

KW - Immune Checkpoint Inhibitors/therapeutic use

KW - Leukemia, Myelogenous, Chronic, BCR-ABL Positive

KW - Leukemia, Myeloid, Acute

KW - Myelodysplastic Syndromes/drug therapy

UR - https://www.scopus.com/pages/publications/85131682357

U2 - 10.1007/s00262-022-03230-4

DO - 10.1007/s00262-022-03230-4

M3 - Article

C2 - 35691988

AN - SCOPUS:85131682357

SN - 0340-7004

VL - 72

SP - 249

EP - 255

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 1

ER -

Hematologic malignancies following immune checkpoint inhibition for solid tumors

Abstract

Keywords

Access to Document

Fingerprint

Cite this